2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1680

Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?
Abstract Number: 1681

Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases
Abstract Number: 1682

Correlation between SLE Specific and Generic Health Related Quality of Life Surveys, and Their Association with Patient Global Rating of Change and Lupus Low Disease Activity State: A Longitudinal Study
Abstract Number: 1683

Variation in HEp-2 Antinuclear Antibody (ANA) Titer Is Strongly Associated with the ANA Kit Manufacturer
Abstract Number: 1684

Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality
Abstract Number: 1685

IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients
Abstract Number: 1686

Rule-Based Algorithm Using Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria to Identify Patients with Systemic Lupus Erythematosus (SLE) from Electronic Health Record (EHR) Data
Abstract Number: 1687

Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales
Abstract Number: 1688

Changes in Heart Rate Variability Reflect Clinical Improvement and Flare in Systemic Lupus Erythematosus
Abstract Number: 1689

Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus
Abstract Number: 1690

Increased Sensitivity Οf Τhe New (2017) Αnd Τhe 2012 SLICC As Compared Τo Τhe Acr 1997 Classification Criteria Ιn Early Systemic Lupus Erythematosus (SLE): The 2017 Αnd 2012 Criteria May Classify Non-Overlapping Subgroups Οf Patients
Abstract Number: 1691

Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns
Abstract Number: 1692

Using ICD-10-CM Codes to Identify Patients with Systemic Lupus Erythematosus in the Electronic Health Record
Abstract Number: 1693

Innate, Adaptive, and TNF-Superfamily Immune Pathways Inform a Lupus Disease Activity Immune Index That Characterizes Disease Activity in SLE
Abstract Number: 1694

The Lupus Severity Index Accurately Identifies Patients with Severe SLE in a Multi-Ethnic Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].